Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update".
作者信息
Braun Juergen
机构信息
Rheumapraxis Berlin, Ruhr University Bochum, Berlin, Germany
出版信息
Ann Rheum Dis. 2023 Sep;82(9):e205. doi: 10.1136/ard-2023-223935. Epub 2023 Feb 3.
Abstract
摘要
相似文献
1
Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update".关于“ASAS-EULAR 轴性脊柱关节炎管理建议：2022 年更新”的通信
Ann Rheum Dis. 2023 Sep;82(9):e205. doi: 10.1136/ard-2023-223935. Epub 2023 Feb 3.
2
Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun .对布劳恩关于“ASAS-EULAR 轴性脊柱关节炎管理建议：2022 年更新”的通信的回复
Ann Rheum Dis. 2023 Sep;82(9):e206. doi: 10.1136/ard-2023-223937. Epub 2023 Mar 6.
3
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.生物改善病情抗风湿药的疗效与安全性：一项系统性文献综述，为2022年更新的ASAS-EULAR轴性脊柱关节炎管理推荐提供依据
Ann Rheum Dis. 2023 Jan;82(1):130-141. doi: 10.1136/ard-2022-223298. Epub 2022 Oct 21.
4
Twenty Years of SPARTAN: From Inception to Impact (SPARTAN 2023 Annual Meeting Proceedings).《SPARTAN 二十年：从创立到影响（SPARTAN 2023 年会论文集）》。
Curr Rheumatol Rep. 2024 Mar;26(3):96-101. doi: 10.1007/s11926-023-01131-8. Epub 2024 Jan 12.
5
To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question.2023 年，中轴型脊柱关节炎是否需要逐渐减少生物靶向改善病情抗风湿药物：这是一个问题。
Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101869. doi: 10.1016/j.berh.2023.101869. Epub 2023 Aug 30.
6
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.非药物和非生物干预措施的疗效与安全性：一项系统文献综述，为2022年更新的ASAS/EULAR轴性脊柱关节炎管理推荐提供依据
Ann Rheum Dis. 2023 Jan;82(1):142-152. doi: 10.1136/ard-2022-223297. Epub 2022 Oct 19.
7
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.关于“随机对照试验中抗白细胞介素-23疗法对轴向性脊柱关节炎无效，但在银屑病关节炎相关‘医生报告的脊柱炎’的事后分析中有效？”的通信
Ann Rheum Dis. 2023 Aug;82(8):e187. doi: 10.1136/annrheumdis-2022-222161. Epub 2022 Apr 29.
8
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.ASAS-EULAR 推荐的中轴型脊柱关节炎管理：2022 更新。
Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.
9
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.关于“抗IL-23疗法在随机对照试验中对轴性脊柱关节炎无效，但在银屑病关节炎相关‘医生报告的脊柱炎’的事后分析中有效？”的通信
Ann Rheum Dis. 2023 Aug;82(8):e185. doi: 10.1136/annrheumdis-2021-221799. Epub 2021 Nov 29.
10
Radiologic approach to axial spondyloarthritis: where are we now and where are we heading?轴向脊柱关节炎的放射学方法：我们现在在哪里，我们的目标在哪里？
Rheumatol Int. 2018 Oct;38(10):1753-1762. doi: 10.1007/s00296-018-4130-1. Epub 2018 Aug 21.
本文引用的文献
1
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.ASAS-EULAR 推荐的中轴型脊柱关节炎管理：2022 更新。
Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.
2
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.巴瑞替尼治疗活动性非放射性中轴型脊柱关节炎（SELECT-AXIS 2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2022 Jul 30;400(10349):369-379. doi: 10.1016/S0140-6736(22)01212-0.
3
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.基线C反应蛋白水平对强直性脊柱炎患者司库奇尤单抗治疗反应的影响：两项III期研究的3年汇总数据
RMD Open. 2018 Nov 21;4(2):e000749. doi: 10.1136/rmdopen-2018-000749. eCollection 2018.
4
Causes of pain in patients with axial spondyloarthritis.中轴型脊柱关节炎患者疼痛的原因。
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):102-107. Epub 2017 Sep 29.
5
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.肿瘤坏死因子阻滞剂通过降低疾病活动度抑制强直性脊柱炎的脊柱影像学进展：来自瑞士临床质量管理队列的结果
Ann Rheum Dis. 2018 Jan;77(1):63-69. doi: 10.1136/annrheumdis-2017-211544. Epub 2017 Sep 22.
6
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.治疗中轴型脊柱关节炎和外周型脊柱关节炎，尤其是银屑病关节炎，以达治疗目标：国际特别工作组2017年推荐更新版
Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.
7
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.2016 年更新的 ASAS-EULAR 中轴型脊柱关节炎管理推荐。
Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13.
8
Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.根据当前建议，非甾体抗炎药治疗影像学和非影像学轴向脊柱关节炎患者的疗效
Rheumatology (Oxford). 2017 Jan;56(1):95-102. doi: 10.1093/rheumatology/kew367. Epub 2016 Oct 25.
9
Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.在活动性强直性脊柱炎患者中，司库奇尤单抗对 MRI 发现与临床疗效的长期影响：一项观察性研究。
Ann Rheum Dis. 2016 Feb;75(2):408-12. doi: 10.1136/annrheumdis-2015-207544. Epub 2015 Aug 6.
10
Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).双氯芬酸治疗强直性脊柱炎连续与按需治疗 2 年对脊柱放射学进展的影响：一项随机多中心试验（ENRADAS）的结果。
Ann Rheum Dis. 2016 Aug;75(8):1438-43. doi: 10.1136/annrheumdis-2015-207897. Epub 2015 Aug 4.
Zotero 插件